Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders
Standard
Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. / Wolff, Markus; Johannesen, Katrine M; Hedrich, Ulrike B S; Masnada, Silvia; Rubboli, Guido; Gardella, Elena; Lesca, Gaetan; Ville, Dorothée; Milh, Mathieu; Villard, Laurent; Afenjar, Alexandra; Chantot-Bastaraud, Sandra; Mignot, Cyril; Lardennois, Caroline; Nava, Caroline; Schwarz, Niklas; Gérard, Marion; Perrin, Laurence; Doummar, Diane; Auvin, Stéphane; Miranda, Maria J; Hempel, Maja; Brilstra, Eva; Knoers, Nine; Verbeek, Nienke; van Kempen, Marjan; Braun, Kees P; Mancini, Grazia; Biskup, Saskia; Hörtnagel, Konstanze; Döcker, Miriam; Bast, Thomas; Loddenkemper, Tobias; Wong-Kisiel, Lily; Baumeister, Friedrich M; Fazeli, Walid; Striano, Pasquale; Dilena, Robertino; Fontana, Elena; Zara, Federico; Kurlemann, Gerhard; Klepper, Joerg; Thoene, Jess G; Arndt, Daniel H; Deconinck, Nicolas; Schmitt-Mechelke, Thomas; Maier, Oliver; Muhle, Hiltrud; Wical, Beverly; Finetti, Claudio; Brückner, Reinhard; Pietz, Joachim; Golla, Günther; Jillella, Dinesh; Linnet, Karen M; Charles, Perrine; Moog, Ute; Õiglane-Shlik, Eve; Mantovani, John F; Park, Kristen; Deprez, Marie; Lederer, Damien; Mary, Sandrine; Scalais, Emmanuel; Selim, Laila; Van Coster, Rudy; Lagae, Lieven; Nikanorova, Marina; Hjalgrim, Helle; Korenke, G Christoph; Trivisano, Marina; Specchio, Nicola; Ceulemans, Berten; Dorn, Thomas; Helbig, Katherine L; Hardies, Katia; Stamberger, Hannah; de Jonghe, Peter; Weckhuysen, Sarah; Lemke, Johannes R; Krägeloh-Mann, Ingeborg; Helbig, Ingo; Kluger, Gerhard; Lerche, Holger; Møller, Rikke S.
in: BRAIN, Jahrgang 140, Nr. 5, 01.05.2017, S. 1316-1336.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders
AU - Wolff, Markus
AU - Johannesen, Katrine M
AU - Hedrich, Ulrike B S
AU - Masnada, Silvia
AU - Rubboli, Guido
AU - Gardella, Elena
AU - Lesca, Gaetan
AU - Ville, Dorothée
AU - Milh, Mathieu
AU - Villard, Laurent
AU - Afenjar, Alexandra
AU - Chantot-Bastaraud, Sandra
AU - Mignot, Cyril
AU - Lardennois, Caroline
AU - Nava, Caroline
AU - Schwarz, Niklas
AU - Gérard, Marion
AU - Perrin, Laurence
AU - Doummar, Diane
AU - Auvin, Stéphane
AU - Miranda, Maria J
AU - Hempel, Maja
AU - Brilstra, Eva
AU - Knoers, Nine
AU - Verbeek, Nienke
AU - van Kempen, Marjan
AU - Braun, Kees P
AU - Mancini, Grazia
AU - Biskup, Saskia
AU - Hörtnagel, Konstanze
AU - Döcker, Miriam
AU - Bast, Thomas
AU - Loddenkemper, Tobias
AU - Wong-Kisiel, Lily
AU - Baumeister, Friedrich M
AU - Fazeli, Walid
AU - Striano, Pasquale
AU - Dilena, Robertino
AU - Fontana, Elena
AU - Zara, Federico
AU - Kurlemann, Gerhard
AU - Klepper, Joerg
AU - Thoene, Jess G
AU - Arndt, Daniel H
AU - Deconinck, Nicolas
AU - Schmitt-Mechelke, Thomas
AU - Maier, Oliver
AU - Muhle, Hiltrud
AU - Wical, Beverly
AU - Finetti, Claudio
AU - Brückner, Reinhard
AU - Pietz, Joachim
AU - Golla, Günther
AU - Jillella, Dinesh
AU - Linnet, Karen M
AU - Charles, Perrine
AU - Moog, Ute
AU - Õiglane-Shlik, Eve
AU - Mantovani, John F
AU - Park, Kristen
AU - Deprez, Marie
AU - Lederer, Damien
AU - Mary, Sandrine
AU - Scalais, Emmanuel
AU - Selim, Laila
AU - Van Coster, Rudy
AU - Lagae, Lieven
AU - Nikanorova, Marina
AU - Hjalgrim, Helle
AU - Korenke, G Christoph
AU - Trivisano, Marina
AU - Specchio, Nicola
AU - Ceulemans, Berten
AU - Dorn, Thomas
AU - Helbig, Katherine L
AU - Hardies, Katia
AU - Stamberger, Hannah
AU - de Jonghe, Peter
AU - Weckhuysen, Sarah
AU - Lemke, Johannes R
AU - Krägeloh-Mann, Ingeborg
AU - Helbig, Ingo
AU - Kluger, Gerhard
AU - Lerche, Holger
AU - Møller, Rikke S
N1 - © The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patch-clamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.
AB - Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patch-clamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.
KW - Adolescent
KW - Adult
KW - Age of Onset
KW - Child
KW - Child, Preschool
KW - Denmark
KW - Epilepsy
KW - Female
KW - Humans
KW - Infant
KW - Male
KW - Mutation
KW - NAV1.2 Voltage-Gated Sodium Channel
KW - Neurodevelopmental Disorders
KW - Phenotype
KW - Sodium Channel Blockers
KW - Young Adult
KW - Journal Article
U2 - 10.1093/brain/awx054
DO - 10.1093/brain/awx054
M3 - SCORING: Journal article
C2 - 28379373
VL - 140
SP - 1316
EP - 1336
JO - BRAIN
JF - BRAIN
SN - 0006-8950
IS - 5
ER -